BCELLSMICETOMEN
Translational study on the antigen presenting properties of human vs mouse B cell subpopulations
| Coordinatore | "THE STEPHAN ANGELOFF INSTITUTE OF MICROBIOLOGY, BULGARIAN ACADEMY OF SCIENCES"
Organization address
address: ACAD GEORGI BONCHEV STREET BL 26 contact info |
| Nazionalità Coordinatore | Bulgaria [BG] |
| Totale costo | 75˙000 € |
| EC contributo | 75˙000 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2009-RG |
| Funding Scheme | MC-IRG |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-04-15 - 2013-04-14 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
"THE STEPHAN ANGELOFF INSTITUTE OF MICROBIOLOGY, BULGARIAN ACADEMY OF SCIENCES"
Organization address
address: ACAD GEORGI BONCHEV STREET BL 26 contact info |
BG (SOFIA) | coordinator | 75˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Our recent results on antitumor effects of carbohydrate mimotope peptides (CMP) suggest a possible role of carbohydrate reactive B cell subpopulations as cellular adjuvants. As an abundant alternative of dendritic cells, CD40-activated B cells can efficiently present specific antigens being expandable for several weeks. Some B cells can be sufficiently detrimental to warrant anti-B cell therapy in cancer. Other (mouse) B cell subsets (e.g. B1 and marginal zone (MZ) B cells) seem as effective as mature DC, including skewing the T cell to the desirable Th1 responses. Thus, B subpopulations deserve scrutiny as the optimal antigen presenting cells. We hypothesize that CMP target carbohydrate reactive B cells, which present the collinear T cell epitopes to auxiliary T cells, create an environment conducive to epitope spreading to glycoprotein tumor antigens. The major mature B cell subpopualtions in the mouse are B2 follicular cells, MZ B cells, as well as B1a and B1b peritoneal B cells. The translation of a B cell strategy to the clinic is hindered by lack of straightforward functional homologies between mouse and human B cell subsets. Therefore, we propose to study the potential of ex vivo expanded human B cell subpopulations to present CMP and induce an appropriate cytokine environment for the development of anti-tumor CTL responses in comparison to the mouse system. To this end we propose to compare the phenotype and antigen presenting properties of mouse and human CMP specific B cells. These studies will allow for the design of therapeutic approaches based on ex vivo expansion of phenotypically similar B cells and using them for active immunotherapy of cancer after loading with appropriate antigens. The relevance of the CMP specific system to a bulk population of the same phenotype stems from the capacity of B cells to present antigens targeted nonspecifically for instance to CD19.'